â??Single-Center, Randomized, Cross-Over, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Combination of Diclofenac Sodium 1% with Triclocarban in Subjects with Painful Diabetic Peripheral Neuropathyâ??

开始日期2012-08-01

申办/合作机构-

100 项与双氯芬酸钠/三氯卡班相关的临床结果

登录后查看更多信息

100 项与双氯芬酸钠/三氯卡班相关的转化医学

登录后查看更多信息

100 项与双氯芬酸钠/三氯卡班相关的专利（医药）

登录后查看更多信息

565

项与双氯芬酸钠/三氯卡班相关的文献（医药）

2026-02-01·JOURNAL OF CHROMATOGRAPHY A

Nontarget screening and suspect identification of organic chlorinated compounds in cosmetics and personal care products using UHPLC-Q-Orbitrap-HRMS

Article

作者: Liang, Wenyao ; Peng, Xianzhi ; Li, Xinling ; Tan, Jianhua ; Yang, Tao

Organic chlorinated compounds have been extensively incorporated into cosmetics and personal care products (CPCPs) as germicides, surfactants, and oil-controlling agents, leading to potential human exposure and associated health risks. However, available research has mostly been limited to several chlorinated compounds in CPCPs, e.g., triclosan and triclocarban. In this study, an integrated analytical framework was established combining isotope-pattern-based nontarget screening with database-assisted suspect identification to comprehensively characterize organic chlorinated compounds in CPCPs. The framework was successfully validated by screening and identification of chlorinated compounds in children's skincare products for sale in China. A total of 227 chlorinated compounds were tentatively identified, including 3 confidence level (CL)1, 9 CL2, 93 CL3, and 122 CL4 compounds with RDBE values of 0 - 29 and molecular masses of 128 - 931 Da. Heterocyclics and ethers were predominant among the CL1-CL3 compounds. Chlorhexidine was quantified maximally at 0.456 %. Triclosan, elubiol, and 4-chloroaniline were also detected in at least one product although they have been banned in skincare products. Overall, the results demonstrated robustness of the comprehensive analytical framework in identifying and characterizing chlorinated compounds in CPCPs. In addition, this research shed light on potential exposure of young children to a cocktail of chlorinated compounds, underscoring urgent need for strict regulations of chemical addition and transparent ingredient labeling to ensure safe use of CPCPs.

2026-02-01·JOURNAL OF CONTAMINANT HYDROLOGY

Fate, chlorination kinetics, and comprehensive risk assessment of pharmaceuticals and personal care products in drinking water distribution systems

Article

作者: Wang, Fei ; Xiao, Minru ; Wei, Anlei ; Li, Nan ; Li, Zhenglin

The widespread occurrence of pharmaceuticals and personal care products (PPCPs) in aquatic environments has emerged as a global concern due to their potential threats to water security and ecological health. Despite increasing attention, their fate and associated risks in drinking water systems remain insufficiently understood. The occurrence, transformation behavior, and ecological and human health risks of 19 PPCPs were investigated across drinking water treatment and distribution systems in this study. Eighteen PPCPs were ubiquitously detected in raw water, with high detection frequencies (>70 %), whereas both the number of detected compounds and their concentrations were markedly reduced in finished water (five compounds) and tap water (eleven compounds). These results demonstrate the substantial effectiveness of conventional treatment processes in reducing both the diversity and concentrations of PPCPs. To further elucidate their potential transformation during water treatment, chlorination kinetics of eight structurally diverse PPCPs were evaluated under controlled conditions. Four compounds (atenolol, sulpiride, paroxetine, and nadolol) exhibited pseudo-first-order kinetics with residual chlorine, while the others exhibited significant resistance to chlorination. Degradation efficiency was found to depend on both the water matrix conditions and their molecular properties, highlighting the combined roles of intrinsic chemical properties and environmental complexity. Ecological risk assessment revealed ibuprofen posed a moderate ecological risk, a risk quotient (RQ) of 0.335, while triclocarban presented a high ecological risk (RQ = 4.6031). Mixture toxicity assessment based on the cumulative toxic unit (ΣTU) further indicated a potential ecological risk (ΣTU > 1) in raw water. Human health risk assessment showed minimal risks across all age groups (RQ 〈10^-3). However, infants were identified as the most susceptible population, likely due to their higher exposure relative to body weight. Among the detected PPCPs, meclofenamic acid was identified as the compound of highest concern, with average relative risk indices exceeding >10^-4. These findings provide critical insights into the fate and transformation of PPCPs in drinking water systems and offer scientific guidance for optimizing treatment processes and risk management strategies.

2026-01-01·ENVIRONMENTAL RESEARCH

Exposure to triclosan and triclocarban is associated with estrogen metabolism in Chinese pregnant women

Article

作者: Lin, Guankai ; Wen, Xiaoting ; Zhao, Ke ; Hong, Sumiao ; Xu, Xiaoyang ; Wang, Yi ; Liu, Jiaqi ; Wang, Na ; Wang, Jiwei ; Huang, Min ; Sun, Baochang ; Jiang, Qingwu ; Chen, Yue ; Chen, Yuanyuan ; Wang, Hexing ; Zhou, You ; Wang, Yuanping ; Lin, Haiping

BACKGROUND:

Exposure to triclosan and triclocarban has been proposed to disrupt estrogen metabolism, but relevant human studies remain limited, especially among pregnant women.

METHODS:

A cross-sectional study was conducted in 432 pregnant women aged 18-42 years selected from the Wenzhou Mother and Child Cohort Study. Urinary concentrations of triclosan, triclocarban, and three estrogens (estrone (E₁), 17β-estradiol (E₂), and estriol (E₃)) were measured by liquid chromatography coupled to mass spectrometry. The associations of urinary triclosan and triclocarban with urinary estrogens were analyzed using linear regression models and restricted cubic spline analysis.

RESULTS:

Triclosan and triclocarban were detected in 60.2 % and 25.9 % of urine samples, respectively. After trichotomizing urinary triclocarban concentrations based on limit of detection and median of urinary creatinine-corrected concentration among positive samples, pregnant women in tertile 3 showed a higher urinary E₁ concentration in the adjusted model (regression coefficient (β) = 0.26, 95 % confidence interval (CI): 0.01, 0.52, p = 0.045). After stratified by pregnancy trimester, for pregnant women in the first trimester of pregnancy, those in tertile 2 of urinary triclosan had a marginally higher urinary E₁ concentration (β = 0.25, 95 %CI: 0.03, 0.47, p = 0.029) and those in tertile 3 showed lower urinary concentrations of E₁ (β = -0.28, 95 %CI: 0.50, -0.05, p = 0.017) and E₂ (β = - 0.19, 95 %CI: 0.36, -0.01, p = 0.034). For pregnant women in the second/third trimester of pregnancy, those in tertile 3 of urinary triclosan had a marginally higher urinary E₁ concentration (β = 0.26, 95 %CI: 0.04, 0.55, p = 0.090). An approximately inverted U shape was observed for the association of urinary triclosan with E₁ and E₂ in the first trimester of pregnancy.

CONCLUSIONS:

Exposure to triclosan and triclocarban may disrupt estrogen metabolism during pregnancy with a difference by pregnancy trimester and some non-monotonic dose responses.

项与双氯芬酸钠/三氯卡班相关的新闻（医药）

2025-07-23

·EINPresswire

Topical Antiseptic Products: Hand Sanitizers and Antibacterial Soaps

FDA is undertaking a review of active ingredients used in a variety of over-the-counter (OTC) antiseptic rubs and wash products. Health care antiseptics are being evaluated separately from consumer antiseptics because they have different proposed use settings and target populations, and the risks for infection in the different settings varies. More information about both is presented below. What are antiseptics? Over-the-counter consumer antiseptics can generally be broken down into two groups: washes and rubs. The definition for each is below. Washes Antiseptic wash products, also known as antibacterial soaps, are intended for use with water and are rinsed off after use, and include hand washes /soaps and body washes. FDA supports the CDC’s recommendation to use plain soap and water to wash your hands. When water is not readily available, a hand sanitizer may be a suitable alternative. Rubs Rubs are leave-on products, or hand “sanitizers,” as well as antiseptic wipes. These products are intended to be used when soap and water are not available, and are left on and not rinsed off with water. Remember: Just like with all over-the-counter drugs, it is important to read the label every time you use hand sanitizers or antiseptic wipes. These products should be stored out of the reach of children and should be used with adult supervision. Use hand sanitizers and antiseptic wipes only as directed on the label. Do not swallow them. If you swallow these products call a poison control center immediately. What is the difference between health care antiseptics and consumer antiseptics? Health Care Antiseptics Health care antiseptics differ from consumer antiseptics in the following ways: They are primarily used by health care professionals in hospitals, clinics, doctors’ offices, outpatient settings and nursing homes. Health care antiseptics are not only used to protect the user but also to protect the patient, whereas consumer antiseptics are generally applied to protect the user. Health care antiseptics are often used more frequently by health care workers than consumers use consumer antiseptics. Consumer Antiseptics Consumer antiseptics differ from healthcare antiseptics in the following ways: Consumer antiseptics are primarily used in the home, schools, daycares or other public settings. Most consumer antiseptics are sold in retail establishments like drug stores and grocery stores. How are health care and consumer antiseptics being evaluated? FDA compares the risks and the benefits for active ingredients under specified conditions of their use to help determine whether that active ingredient is generally recognized as safe and effective (GRASE). Since FDA’s 1994 evaluation of OTC antiseptics, many things have changed, including the frequency of use of some products, new technology that can detect low levels of antiseptics in the body, FDA’s safety standards, and scientific knowledge about the impact of widespread use. FDA’s current effort is designed to ensure that the safety and effectiveness evaluations and determinations for active ingredients used in antiseptics are consistent, up-to-date, and appropriately reflect current scientific knowledge and increasing use patterns. Safety FDA proposed that data was needed from a standard battery of tests that is used to determine the safety of many drugs, including OTC antiseptics. This array of tests has changed over time to incorporate improvements in safety testing. For more specific information on safety tests, please see the final rule on consumer antiseptic washes , the final rule on health care antiseptics , and the final rule on consumer antiseptic rubs . Efficacy For consumer antiseptic washes , millions of Americans use antiseptic hand soaps and body washes each day, but these products have not yet been shown to be more effective at preventing illness than plain soap and water. Additionally, emerging data have raised concerns that long-term, daily use of these products may outweigh their presumed benefits. The clinical studies data on effectiveness would specifically need to demonstrate that the active ingredients in consumer antiseptic wash products are superior to non-antibacterial soap in preventing illness or reducing infection. FDA has issued a final rule requiring the removal of certain active ingredients from OTC consumer antibacterial hand soaps and body washes including the most commonly used triclosan and triclocarban. Antibacterial manufacturers did not provide the necessary data to demonstrate the effectiveness for these active ingredients and so the FDA could not determine that they are generally recognized as safe and effective for use in consumer antiseptic washes. For more specific information on effectiveness testings for active ingredients used in consumer antiseptic washes, please see the final rule on consumer antiseptic washes . FDA is not proposing clinical outcome studies for active ingredients when used in health care antiseptics or in consumer antiseptic rub products. FDA is requiring clinical simulation studies for health care antiseptics because of ethical concerns with conducting studies in the health care setting; FDA is requiring the clinical simulation studies for consumer antiseptic rubs because these products are intended for use when soap and water are not available, and so they need not demonstrate clinical effectiveness compared to soap and water. For specific information on the efficacy data requested for health care antiseptics and consumer antiseptic rubs, please see the final rules on health care antiseptics and final rule on consumer antiseptic rubs and their respective dockets. Regulatory Information More information Health care antiseptics Content current as of: 06/18/2020 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.